Dyadic International, Inc.

Attending BIO Partnering @JPM Week 2025? Click below to send Dyadic International, Inc a meeting request in the BIO partnering system! #JPM2025 https://lnkd.in/eQS5RVsc

Dyadic Launches a Potentially More Efficient Biomanufacturing Process for DNA/RNA Enzymes and Other Proteins Dyadic International, Inc. (NASDAQ: DYAI) is proud to announce the launch of a cutting-edge biomanufacturing process utilizing its proprietary C1 and Dapibus™ protein expression platforms. These platforms are capable of producing large quantities of enzymes, such as DNase I, and other proteins like transferrin, at a low cost using standard microbial bioreactors. This innovation supports Dyadic’s commitment to increasing global access to affordable enzymes, antigens, monoclonal antibodies, and other proteins critical for health and biomanufacturing needs. To learn more about how Dyadic is driving progress in biomanufacturing, contact us at ir@dyadic.com or visit www.dyadic.com.

Let's meet up at Bio-Europe! Excited to connect and discuss our work with Dyadic International, Inc. C1 and Dapibus Fungal Microbial Platforms. We are continuing to expand the adoption of our rapid and efficient C1 and Dapibus filamentous fungal protein production platforms to accelerate the development and manufacturing of enzymes, antigens, monoclonal antibodies and other proteins for pharmaceutical and non pharmaceutical applications globally. Let’s work together to create synergistic solutions that can impact global health, nutrition and wellbeing. Drop us a note to schedule some time together! #antigens #monoclonalantibodies #vaccines #enzyme #alternative #proteins #food #dairy #albumen #DNase1

Let's meet up at Bio-Europe! We would love to connect with you and tell you about what we are working on with our C1 and Dapibus Fungal Microbial Platforms! Please drop us a note so we can schedule time together! #antigens #monoclonalantibodies #vaccines #enzyme #alternative #proteins #food #dairy #albumen #DNase1

The "Today’s Bull Run" podcast hosted by Charlie Davanzo features two companies, Unicycive Therapeutics #UNCY and Dyadic International, Inc. #DYAI that are using technology to impact the world. Unicycive, founded by Dr. Shalabh Gupta, MD , focuses on developing treatments for renal diseases and other unmet medical needs. The company has spent several years refining its technologies and building a unique biotech system for discovering and developing promising treatments. Dyadic's journey began with the search for a microorganism to soften denim, resulting in the discovery of the fungus Thermothelomyces heterothallica. This discovery led to the development of the C1 platform, which is being used to create a wide range of products in areas such as pharmaceuticals, food, and nutrition. https://lnkd.in/e2sixeDp

Heart disease and other diseases can be prevented if lifesaving medicines, including biologics, are made accessible and affordable globally. Unfortunately, the current methods of developing and manufacturing these medicines are barriers to access, especially in low- and middle-income countries. It is time for a change. Limitations of Current Production Platforms: 1. Vaccine Antigen Production (Baculovirus/Insect Cells): • Baculovirus (insect cells) are slower and less productive compared to advanced systems, leading to higher costs and limiting global vaccine access. 2. Monoclonal Antibody (mAb) Production (CHO Cells): • CHO cells are slow-growing, expensive, and keep mAb treatments out of reach for lower-income countries. Call to Action Governments, industry, and academia must adopt more efficient cell lines like Dyadic International, Inc. C1 platform. The world has the technology to make biologics faster, cheaper, and more accessible—what’s needed is the will to act.

#vaccines #antigens #monoclonalantibodies

Exciting times at Dyadic! Please reach out for samples! #Transferrin #alphalactalbumin #DNASE #Hyaluronidase #betalactoglobulin

Let's meet up in Boston at BPI!! #antigens #vaccines #recombinantalbumin #transferrin #lactoferrin #DNASE

It’s the same old story, lack of adopting innovative approaches to solving problems due to either doing the same thing over and over again and expecting different results, or the not invented here syndrome. As Robert (Bobby), Kennedy was quoted, for clarification, President JFK’s brother; “Some men see things as they are and ask, Why?, I dream things that never were and ask, Why not?" Why not enable Africa and other Continents to develop and manufacture their own medicines using smaller, more efficient and lower cost manufacturing methods. Dyadic International, Inc. we are doing just that, for example our partnership with South African University of the Witwatersrand - Rubic one Health. To join this effort please reach out to us at ir@dyadic.com (Nasdaq:DYAI) https://lnkd.in/eXsv_FF5